■ ABL Bio said on the 5th that its subsidiary Neok Bio will officially launch in the United States. Neok Bio is a corporations specializing in clinical development of bispecific antibody ADCs (antibody-drug conjugates). ADCs are a treatment technology that attaches a drug to an antibody to deliver it precisely to cancer cells only. The company disclosed the BL206 and ABL209 targets for the first time. In nonclinical studies, efficacy and safety improved over existing monospecific antibody ADCs, and they are being developed as new drugs for patients with solid tumors.
■ SK bioscience said on the 5th that its European subsidiary IDT Biologika has entered the global CDMO (contract development and manufacturing) bidding race. The company took part in WVC 2025 in the Netherlands, CPHI 2025 in Germany, and BioEurope 2025 in Austria, showcasing manufacturing solutions and partnership strategies.
■ Daewoong Pharmaceutical said on the 5th that it recently participated in the CPHI 2025 pharmaceutical and biotech exhibition in Germany. It introduced technologies including its flagship new drugs, microneedles (micro-needles), and biosimilars (biologic drug copies) and pursued contracts.
■ DuChemBio said on the 5th that it has unveiled Prostacyc, a radiopharmaceutical for diagnosing prostate cancer. By tracking a specific protein overexpressed in prostate cancer cells, it increased the detection rate for recurrent patients. It shortened the test time from the previous 3–4 hours to 80 minutes.
■ SR Co. Therapeutics said on the 5th that it will newly appoint professional manager Choi Heon as CEO. The company recently signed a memorandum of understanding with Chong Kun Dang for cooperation on a prototype digital therapeutic to curb pediatric myopia.
■ Next Biomedical said on the 5th that its partner Century Medical recently took part in the JDDW 2025 gastroenterology meeting in Japan. It introduced NexPowder, an endoscopic wound covering material, and delivered an academic presentation. JDDW is an international academic event integrating the societies of gastroenterology, gastrointestinal endoscopy, hepatology, gastrointestinal surgery, and gastrointestinal cancer screening.
■ Celltrion said on the 5th that its multispecific antibody immuno-oncology drug CT-P72/ABP-102 under development demonstrated safety and efficacy in animal studies. The company will present the findings at a U.S. immuno-oncology conference.
■ Koh Young Technology said on the 5th that a paper on its brain surgery medical robot, Kymero, was published in JNS, the journal issued by the American Association of Neurological Surgeons. A research team led by Professor Jang Won-seok of the Department of Neurosurgery at Yonsei University Severance Hospital spearheaded the paper. A company official said, "Hospital demand is increasing in the United States."
■ Oh Juhan, an orthopedic surgeon at Seoul National University Bundang Hospital, has taken office as president of the Korean Orthopaedic Association. The term is one year. Founded in 1956, the Korean Orthopaedic Association works to promote the public's musculoskeletal health. Oh is an expert in shoulder disorders and sports medicine.
■ SELVAS AI said on the 5th that it signed a joint development agreement with Inje University Busan Paik Hospital to build a smart hospital. SELVAS AI will develop an artificial intelligence (AI) medical record system tailored to the hospital based on its medical data. The company said AI can reduce administrative workloads and improve the efficiency of care.
■ Boehringer Ingelheim Korea said on the 5th that it conducted a campaign for the All Hope's Voice Choir under the Korea Organization for Rare Disorders. It gave lectures to people with rare diseases and their families on how to manage mental health in daily life and care for their minds. It also provided digital education using tablet PCs.